The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study
ConclusionsUpdated results from the FACOS study support the benefits of oxaliplatin-based adjuvant chemotherapy in terms of the long-term survival among Japanese patients with stage III colon cancer. However, long-term persistent PSN occurs in about 20% of survivors, counterbalancing the favorable OS.
Source: Surgery Today - Category: Surgery Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Chemotherapy | Colon Cancer | Colorectal Cancer | Eloxatin | Japan Health | Neurology | Neurosurgery | Study | Surgery